Latest news:

  • February 2017
  • January 2017
    • The United States Patent & Trademark Office has issued a Notice of Allowance for the first patent (DIAGNOSTIC METHOD)
  • December 2016
    • Pre Diagnostics awarded EUR 0,8 mill in a research grant from the Norwegian Research Council
  • May 2016
  • November 2015
  • October 2015
    • Pre Diagnostics presenting at the Biomarker Summit Europe 2015 in Berlin
  • April 2015
    • Pre Diagnostics presenting at the One Nucleus Dementia Investment Forum in London
  • March 2015
    • Pre Diagnostics presenting at the Sachs Life Science CEO meeting in Zürich
  • February 2015
    • Pre Diagnostics awarded NOK 200k from the Regionale Forskningsfond supporting a clinical intervention study
  • September  2014
    • Pre Diagnostics awarded  NOK 4 mill from the IFU/OFU program of Innovation Norway
      • Pre Diagnostics, in partnership with Fürst Medisinsk Laboratorium and Akershus University Hospital, aims to develop the current prototype test to a CE-approved diagnostic for pre-dementia diagnosis of Alzheimers ready for the European market by 2016.
  • September 2014:
    • Press release (in Norwegian) “NORSK GJENNOMBRUDD I ALZHEIMERS-FORSKNINGEN”.

 

About Pre Diagnostics AS

Pre Diagnostics is an innovative Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases.

The company’s proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients.

Pre Diagnostics aims to be a leader in the diagnosis of early Alzheimer’s disease and is thus focused on the development of IVD biomarker products that use well-established technologies and procedures.

The company protects its technology with an evolving patent portfolio.